Please use this identifier to cite or link to this item:
Title: Are patients with cancer receiving adequate treatment for thrombosis? Results from FRONTLINE
Authors: Wong, J.E.-L. 
Keywords: Cancer patients
Clinician survey
Low-molecular-weight heparin (LMWH)
Thrombosis treatment
Venous thromboembolism
Issue Date: Jun-2003
Citation: Wong, J.E.-L. (2003-06). Are patients with cancer receiving adequate treatment for thrombosis? Results from FRONTLINE. Cancer Treatment Reviews 29 (SUPPL. 2) : 11-13. ScholarBank@NUS Repository.
Abstract: The current practice of clinicians worldwide in the treatment of venous thromboembolism was assessed via responses to the FRONTLINE survey. Significant regional differences in practice were noted. Use of low-molecular-weight heparin was reported as the most common initial treatment for venous thromboembolism, although, in North America, unfractionated heparin was widely used to treat surgical cancer patients after a thrombotic episode. Oral anticoagulants were favoured for long-term treatment of venous thromboembolism, particularly in Western Europe and North America. Case study reports from the survey revealed that a substantial proportion of patients with cancer had been perceived to be at low risk of thrombosis, had consequently not received thromboprophylaxis and developed VTE. © 2003 Elsevier Science Ltd. All rights reserved.
Source Title: Cancer Treatment Reviews
ISSN: 03057372
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Page view(s)

checked on Jul 26, 2018

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.